A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Inclusion Criteria: 1. Voluntary participation in clinical studies; 2. Male or female, aged ≥ 18 years; 3. Pathologically or clinically confirmed (according to AASLD), unresectable locally advanced and/or metastatic HCC; 4. Child-Pugh liver function score ≤7； 5. No prior systemic therapy for locally advanced or metastatic and/or unresectable HCC； 6. At least 1 measurable lesion ； 7. Adequate organ function； 8. ECOG score of 0 to 1； 9. Life expectancy ≥ 12 weeks; Exclusion Criteria: 1. Pathologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma and other components； 2. History of serious allergic diseases； 3. The toxicity of previous anti-tumor therapy has not been alleviated； 4. History of severe cardiovascular diseases within 6 months; 5. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions; 6. History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation; 7. History of alcohol abuse, psychotropic substance abuse or drug abuse; 8. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome; 9. Pregnant or lactating women; 10. Other conditions considered unsuitable for this study by the investigator.